My Cart

Integrin alpha 5 beta 1

Integrin alpha 5 beta 1 Overview

English NameIntegrin alpha-5/beta-1Approved Drugs1
Drugs in Clinical Trials4Target SynonymIntegrin alpha5beta1
Highest Development StageApproved
English NameIntegrin alpha-5/beta-1
Target SynonymIntegrin alpha5beta1
Approved Drugs1
Drugs in Clinical Trials4
Highest Development StageApproved

Integrin alpha 5 beta 1 Product List

  • Product Category

    Protein (3)

  • Product Status

    Launched (3)

  • Species

    Human (2)Cynomolgus (1)

  • Tag

    His Tag (2)His Tag & Avi Tag (1)

  • Conjugate

    Unconjugated (2)Biotin-labeled (1)

Integrin alpha 5 beta 1 Background

Integrin alpha 5 beta 1 / Integrin α5β1, which is a major cellular receptor for the extracellular matrix protein fibronectin and plays a fundamental role during mammalian development., is composed of α5 (ITGA5/CD49e) and β1 (ITGB1/CD29) subunits. Integrins are adhesion receptors that transmit bidirectional signals across the plasma membrane. The Integrin alpha 5 beta 1 and its primary extracellular matrix ligand fibronectin (Fn) are of great biological importance.

Integrin alpha 5 beta 1 Synonyms

Integrin alpha 5 beta 1,ITGA5&ITGB1

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
RisuteganibALG-1001; AM011; AM-011(Allegro Ophthalmics)Phase 1 ClinicalAllegro Ophthalmics LlcDiabetic macular oedema; Diabetic Retinopathy; Geographic Atrophy; Macular Degeneration
Details
Pegylated recombinant human endostatin (Tsinghua University)M-2ES; CRB-0401Phase 1 ClinicalBeijing Proji Pharmaceutical Technology Co Ltd, Beijing Protgen Biotechnology Development Co Ltd, Tsinghua UniversityCarcinoma, Non-Small-Cell Lung; Neoplasms; Pancreatic Neoplasms; Solid tumours
Details
VAX-014VAX-014Phase 1 ClinicalVaxiion Therapeutics LlcSolid tumours
Details
Integrin α5β1 therapy (Eli Lilly and Company)Phase 1 ClinicalEli Lilly And CompanyCardiovascular Diseases
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Recombinant human endostatin (Simcere)YH-16ApprovedJiangsu Simcere Pharmaceutical Co LtdEndostar, 恩度, EnduMainland ChinaCarcinoma, Non-Small-Cell LungShandong Xiansheng Zaiming Biopharmaceutical Co Ltd2005-09-12Ascites; Brain metastases; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Nasopharyngeal Carcinoma; Osteosarcoma; Pleural Effusion, Malignant
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland